• 12/17/2017

    PAION grants exclusive license to Mundipharma for development and commercialization of remimazolam in Japan

  • 11/14/2017

    FDA considers current human abuse liability program with Remimazolam in the U.S. as sufficient; no second intranasal study required

  • 07/17/2017

    PAION AG raises EUR 8.0 million in private placement

  • 06/28/2017

    PAION reports positive headline data in U.S. Phase III trial with remimazolam for procedural sedation during bronchoscopy

  • 03/27/2017

    PAION successfully completes patient recruitment in U.S. Phase III study with remimazolam for procedural sedation during bronchoscopy

  • 03/26/2017

    PAION reports positive headline data in U.S. clinical safety trial of remimazolam in high-risk patients undergoing colonoscopy

  • 02/07/2017

    PAION AG to issue approx 2.4 Million Shares at EUR 2.05 per share in capital increase with subscription rights